IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Metrics to compare | IDLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIDLDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.8x | −2.1x | −0.5x | |
PEG Ratio | −0.10 | −0.03 | 0.00 | |
Price/Book | 0.6x | 1.2x | 2.6x | |
Price / LTM Sales | 1.6x | 2.9x | 3.2x | |
Upside (Analyst Target) | 177.8% | 27.8% | 50.1% | |
Fair Value Upside | Unlock | 27.1% | 8.6% | Unlock |